Clinical and Translational Oncology

, Volume 8, Issue 3, pp 200–207

Complementary and alternative medicine (CAM) in Mexican patients with cancer

  • Raquel Gerson-Cwillich
  • Alberto Serrano-Olvera
  • Alberto Villalobos-Prieto
Research Articles

Abstract

Background

Cancer is the second cause of death in Mexico, most cases are detected at advanced stages and the use of chemotherapy is frequent. At present, more than 300 types of complementary and/or alternative medicine (CAM) treatments are known that offer different therapeutic objectives. Many patients use this type of treatments.

Objective

To determine the characteristics of the patients that use CAM, to identify the aim of these treatments, the source of information and the potential benefits obtained by the patient.

Patients and methods

A questionnaire was applied from February 20 to March 5, 2004 to non-selected patients with cancer in private consultation to determine age, sex, education level, work, use of CAM, type and number of used therapies, potential benefits and monthly cost. Two groups were formed, A for users and B for non-users of CAM. Results between groups were compared and the mentioned variables were correlated with the use of alternative medicine.

Results

Group A included 37 patients and group B included 38, with no difference regarding age, education level, work and oncological diagnosis, p> 0.05; a significant trend was found as regards the feminine sex, p=0.07, neoplasm different from breast cancer, p=0.08 and evident association with neoplasm advanced stages, p=0.02. Most patients used between 1 and 3 types of therapies, 97.2%. The most common types of therapies were nutritional and spiritual, 54% and 48.6%, respectively. The source was the patient's family in 56.4% and the physician in 24.3%. Complementary and alternative therapy was considered a success in 57.1%; most of the users mentioned benefits (78.6%) deemed as tranquility (46.4%) or improvement of the physical condition (46.4%). The average monthly cost was $ 345.5 dollars, with a range of $ 13.6 to $2,545.5 dollars.

Conclusions

The use of complementary and/or alternative therapy is frequent among young women with advanced cancer and high level of education. The family participates in the decision of using these methods; most users noticed a benefit in their general condition and reported tranquility; these patients may be prone to higher incidence of depression and anxiety. The effectiveness and safety of this type of treatments remain to be determined, as well as the possible interactions with conventional therapy.

Key words

cancer complementary and alternative medicine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    www.dgepi.salud.gob.mx/diveent/DI-VEENT-INDEX.htm. Registro Histopatológico de Neoplasias en México. Dirección General de Epidemiología. Secretaria de Salud, 2001.Google Scholar
  2. 2.
    Serrano A, Gerson R. El cáncer, la muerte y la tanatología. Revista Internacional de Tanatología y Suicidio. 2004;IV:7–10.Google Scholar
  3. 3.
    Chu E, De Vita VT Jr. Principles of medical oncology. In: De Vita VT Jr, Hellman S, Rosemberg SA. Cancer: principles and practice of oncology. 7th edition. Philadelphia, USA: Lippincott Williams & Wilkins, 2005, p. 295–306.Google Scholar
  4. 4.
    Ernst E. Obstacles to research in complementary and alternative medicine. MJA. 2003, p. 279.Google Scholar
  5. 5.
    Cassileth BR. Alternative and complementary cancer treatments. The Oncologist. 1996;1:173–9.PubMedGoogle Scholar
  6. 6.
    Weiger WA, Smith M, Boon H, Richardson MA, Kaptchuk TJ, Eisenberg DM. Advising patients who seek complementary and alternative medical therapies for cancer. Ann Inter Med. 2002;137:889–903.Google Scholar
  7. 7.
    Eisenberg DM, Kessler RC, Foster C, et al. Uncoventional medicine in the United States: prevalence, costs and patterns of use. N Engl J Med. 1993;328:246–52.PubMedCrossRefGoogle Scholar
  8. 8.
    Astin JA. Why patients use alternative medicine: results of a national study. JAMA. 1998;279:1548–53.PubMedCrossRefGoogle Scholar
  9. 9.
    Frenkel M, Ben-Arye E, Baldwin CD, Sierpina V. Approach to communicating with patients about the use of nutritional supplements in cancer care. South Med J. 2005;98:289–94.PubMedCrossRefGoogle Scholar
  10. 10.
    Richardson MA, Masse LC, Nanny K, Sanders C. Discrepant views of oncologist and cancer patients on complementary/alternative medicine. Support Care Cancer. 2004;12:797–804.PubMedCrossRefGoogle Scholar
  11. 11.
    Downer SM, Cody MM, McCluskey P, et al. Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BJM. 1994;309:86–9.Google Scholar
  12. 12.
    Paltiel O, Avitzour M, Peretz T, et al. Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol. 2001;19:2459–48.Google Scholar
  13. 13.
    Martel D, Bussieres JF, Theoret Y, Lebel D, Kish S, Moghrabi A, et al. Use of alternative and complementary therapies in children with cancer. Pediatr Blood Cancer. 2005;44:660–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Kelly KM. Complementary and alternative medical therapies for children with cancer. Eur J Cancer. 2004;40:2041–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Dy GK, Bekele L, Hanson LJ, Furth A, Mandreakar S, Sloan JA, Adjei AA. Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol. 2005;23:248.Google Scholar
  16. 16.
    Burstein HJ, Gelber S, Guadagnoli E, et al. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med. 1999;340:1733–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Navo MA, Phan J, Vaughan C, et al. An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol. 2004;22:671–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Boon H, Westlake K, Steward M, Gray R, Fleshner N, Gavin A, et al. Use of complementary and alternative medicine in men diagnosed with prostate cancer: prevalence and characteristics. Urology. 2005; 62:849–55.CrossRefGoogle Scholar
  19. 19.
    Hyodo I, Amano K, Eguchi K, Narabayashi M, Imanishi J, Harai M, et al. Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol. 2005;25:2645–54.Google Scholar
  20. 20.
    Maher EJ, Young T, Feigel I. Complementary therapies used by patients with cancer. Br Med J. 1994;309:671–2.Google Scholar
  21. 21.
    Lee MM, SS Lin, Wrensch MR, et al. Alternative therapies used by women with breast cancer in tour ethnic populations. J Nat Cancer Inst. 2000;92:42–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Liu JM, Chu HC, Chin YU, et al. Cross sectional study of use alternative medicines in Chinese cancer patients. Jpn J Clin Oncol. 1997;27:37–41.PubMedCrossRefGoogle Scholar
  23. 23.
    Richardson MA, Sanders T, Palmer JL, et al. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000;18:2505–14.PubMedGoogle Scholar
  24. 24.
    Werneke U, Earl J, Seydel C, Horn O, Crichton P, Fannon D. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer. 2004;91:995–6.Google Scholar
  25. 25.
    Chrystal K, Allan S, Forgeson G, Isaacs R. The use of complementary and alternative medicine in cancer patients in a New Zealand regional cancer treatment centre. N Z Med J. 2005;116:U296.Google Scholar
  26. 26.
    Bernstein BJ, Grasso T. Prevalence of complementary and alternative medicine use in cancer patients. Oncology (Huntingt). 2001;15:1267–72.Google Scholar
  27. 27.
    Kim MJ, Lee SD, Kim DR, Kong YH, Sohn WS, Ki SS, et al. Use of complementary and alternative medicine among Korean cancer patients. Korean J Inter Med. 2004; 19:250–6.CrossRefGoogle Scholar
  28. 28.
    Diefenbach MA, Hamrick N, Uzzo N, Pollack A, Horwitz E, Greenberg R, et al. Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with localized prostate cancer. J Urol. 2003;170:166–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Ashikaga T, Bosompra K, O'Brien P, Nelson L. Use of complimentary and alternative medicine by breast cancer patients: prevalence, patterns and communication with physicians. Support Care Cancer. 2002;10:542–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Tough SC, Johnston DW, Verhoef MJ, Arthur K, Bryant H. Complementary and alternative medicine by men diagnosed with prostate cancer: prevalence and characteristics. Urology. 2003;62:849–53.CrossRefGoogle Scholar
  31. 31.
    Nagel G, Hoyer H, Katemkamp D. Use of complementary and alternative medicine in patients with breast cancer: observations from a health care survey. Support Care Cancer. 2004;12:789–96.PubMedCrossRefGoogle Scholar
  32. 32.
    Shen J, Andersen R, Albert PS, Wenger N, Glaspy J, Cole M, et al. Use of complementary and alternative therapies by women with advanced stage breast cancer. BMC Complement Altern Med. 2002;13:8.CrossRefGoogle Scholar
  33. 33.
    Swisher EM, Cohn DE, Goff BA, Parham J, Herzog TJ, Rader JS, et al. Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol. 2002;84:365–7.CrossRefGoogle Scholar
  34. 34.
    Carlsson M, Arman M, Backman M, Flatters U, Hatschek T, Hamrin E. Evaluation of quality of life/life satisfaction in women with breast cancer in complementary and conventional care. Acta Oncol. 2004;43:27–34.PubMedCrossRefGoogle Scholar
  35. 35.
    Adams KD, Cohen MH, Eisenberg D, Jonsen AR. Ethical consideration of complementary and alternative medical therapies in conventional medical settings. Ann Inter Med. 2002;137:660–4.Google Scholar
  36. 36.
    Markman M. Safety issues in using complementary and alternative medicine. J Clin Oncol. 2002;20(18 Suppl):59S-41.Google Scholar
  37. 37.
    Mills E, Ernst E, Singh R, et al. Health food store recommendations: implications for breast cancer patients. Breast Cancer Research. 2003;5:170–3.CrossRefGoogle Scholar

Copyright information

© FESEO 2006

Authors and Affiliations

  • Raquel Gerson-Cwillich
    • 1
  • Alberto Serrano-Olvera
    • 2
    • 4
  • Alberto Villalobos-Prieto
    • 3
  1. 1.Medical Oncology ServiceABC Medical CenterMexico CityMexico
  2. 2.Clinical Research Department of the National Institute of CancerologyMexico CityMexico
  3. 3.Hematology ServiceABC Medical CenterMexico CityMexico
  4. 4.Subdirección de Investigación ClínicaInstituto Nacional de CancerologiaMéxico

Personalised recommendations